Home/Pipeline/AVTX-002

AVTX-002

Non-COVID-19 Acute Lung Injury / ARDS

Phase 2bActive / PlannedNCT05778938

Key Facts

Indication
Non-COVID-19 Acute Lung Injury / ARDS
Phase
Phase 2b
Status
Active / Planned
Company

About Avalo Therapeutics

Avalo Therapeutics is a U.S.-based, clinical-stage biotechnology company with a mission to develop and commercialize targeted therapeutics for significant unmet needs in immunology and immuno-oncology. Its core strategy involves advancing a pipeline of immune-modulating assets through clinical development, aiming for proof-of-concept data and strategic partnerships. The company operates as a public entity, navigating the high-risk, high-reward landscape of drug development, with its valuation heavily influenced by clinical trial catalysts and financing events.

View full company profile